Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01693718
Other study ID # 12141B
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2003
Est. completion date September 2004

Study information

Verified date January 2024
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the study is to test a particular combination of drugs and determine their ability to completely eliminate head and neck cancer.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date September 2004
Est. primary completion date September 2003
Accepts healthy volunteers No
Gender All
Age group 59 Years and older
Eligibility Eligibility Criteria: 1. Patients with Stage IV carcinoma of the nasal or oral cavity, nasopharynx pharynx, larynx, paranasal sinuses, cervical esophagus, or hypopharynx are eligible. Patients with Stage III carcinoma of the nasopharynx, base of tongue and hypopharynx are also eligible. Therapy is given with curative intent. Prior to entry in the study the resectability and standard treatment options for each patient will be determined during a joint evaluation by a team composed of an attending surgeon, a radiation oncologist and a medical oncologist. In addition the timing and feasibility of surgery will be determined in each patient prior to initiation of therapy. The unequivocal demonstration of distant metastasis confers in eligibility. 2. Measurable disease is not required, but all disease will be carefully evaluated. 3. Patients must have a histologically or cytologically confirmed diagnosis of squamous cell carcinoma or lymphoepithelioma. 4. Patients must have not received prior chemotherapy or radiotherapy. 5. Patients must have performance status of >60% 6. Patients must have a WBC count of >3.5, an ANC count >1500 and a platlet count of >100,000. 7. The serum creatinine must be equal to or less than 1.5 m/dlor the calculated creatinine clearance must exceed 50cc/min. 8. Patient must be free of significant infection or other severe complicating medical illness. 9. Pregnancy will constitute an absolute contraindication to entrance on this protocol. Females of child-bearing age should be using adequate contraception.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxyurea
Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
5- Fluorouracil
Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs. Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy.
Cisplatin
Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output > 100 cc/ hour.

Locations

Country Name City State
United States The University of Chicago Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Rates To evaluate the activity of 5 cycles of C-FHX/G-CSF in previously untreated patients with stage II and IV locoregionally advanced head and neck cancer. 2-5 years
Secondary Feasibility of administering adjuvant CRA and interferon alfa2a To determine the feasibility of administering adjuvant CRA and interferon alfa2a for up to one or until tumor progression in patients completing local therapy. 2-5 years
Secondary Side effects of study regimen To determine the pattern and degree of clinical toxicity of this regimen 2-5 years
See also
  Status Clinical Trial Phase
Completed NCT00661427 - Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 2
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Recruiting NCT00733434 - The Use of Prostaglandin E1 in Head and Neck Microsurgery Phase 4
Recruiting NCT03053310 - Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer